小细胞肺癌免疫治疗疗效预测指标的现状与未来

Inhibitions of immune checkpoints, including programmed cell death 1-programmed cell death-ligand 1 (PD-1-PD-L1) axis, cytotoxic T lymphocyte associated antigen-4, are at the forefront of immunotherapy for small cell lung cancer. However, the survival benefits emerged after three to six months since therapy initiation. A growing body of evidence suggested that the current biomarkers were not consistent and convincing. Here, we review the current biomarkers including PD-L1, tumor mutation burden, DNA damage response pathway. Furthermore, we elucidate the potential biomarkers, such as tumor-infiltrating lymphocytes, circulating tumor cells.